Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | PRKX | P51817 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756846 | 0.85 | MEN1 (0.42) | S1PR1S1PR5 | |
| SCHEMBL5759570 | 0.75 | TLR9 (0.51) | TLR9TLR7 | |
| SCHEMBL6452344 | 0.71 | TLR9 (0.51) | TLR9TLR7 | |
| SCHEMBL5755079 | 0.68 | NPC1 (0.60) | — | |
| SCHEMBL20805183 | 0.68 | GRM5 (0.45) | TLR9TLR7 | |
| SCHEMBL5779644 | 0.66 | MAOB (0.57) | — | |
| SCHEMBL27563776 | 0.66 | MAOB (0.57) | — | |
| SCHEMBL4840104 | 0.66 | HPGDS (0.58) | SIGMAR1 | |
| SCHEMBL16319277 | 0.65 | MAOB (0.56) | PTGER1 | |
| SCHEMBL3712815 | 0.65 | MAOB (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | TLR9 568/4885TLR7 190/4885PTGER1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.